Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug...

|About: Baxter International Inc (BAX)|By:, SA News Editor

Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug immunoglobulin (IG) - always a long shot - failed to meet its co-primary endpoints. (PR)